With a strong track record in venture capital, the fund manager has successfully executed over 30 deals across Europe and North America. Their investment focus spans biotechnology, digital health, and medical devices, emphasizing early-stage opportunities. Backed by a data-driven approach, they prioritize operator-first strategies to nurture portfolio companies towards notable exits. This strategic style has enabled them to build a diverse and resilient portfolio that addresses emerging health challenges.